Treatment of Renal Allograft Polyoma BK Virus Infection with Leflunomide
Authors:
- Daniel GillenDGDaniel Gillen
- Basit JavaidBJBasit Javaid
- Pradeep KadambiPKPradeep Kadambi
- Shane MeehanSMShane Meehan
- Preston FosterPFPreston Foster
- Robert HarlandRHRobert Harland
- Richard J. ThistlethwaiteRTRichard J. Thistlethwaite
- Marc GarfinkelMGMarc Garfinkel
- Walter AtwoodWAWalter Atwood
- Joslynn JordanJJJoslynn Jordan
- Molly SadhuMSMolly Sadhu
- 15 March 2006
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 81 (5) , 704-710
Abstract
Polyoma BK virus produces an aggressively destructive nephropathy in approximately 3% to 8% of renal allografts, is associated with graft loss within one year in 35% to 67% of those infected and there is no therapy of proven efficacy. Leflunomide is an immune suppressive drug with anti viral activity in vitro and in animals. We treated twenty-six patients with biopsy proven NK virus nephropathy (BKN) with either leflunomide alone (n=17) or leflunomide plus a course of cidofovir (n=9) and followed them for six to forty months. Leflunomide was dosed to a targeted blood level of active metabolite, A77 1726, of 50 microg/ml to 100 microg/ml (150 microM to 300 microM). Response to treatment was gauged by serial determinations of viral load in blood and urine (PCR), serum creatinine, and repeat allograft biopsy. In the 22 patients consistently sustaining the targeted blood levels of active drug, blood and urine viral load levels uniformly decreased over time (P<.001). Mean serum creatinine levels stabilized over the first six months of treatment, and with 12 months or more of follow-up in 16 patients the mean serum creatinine has not changed significantly from base line. Four patients who did not consistently have blood levels of active drug (A77 1726) above 40 microg/ml did not clear the virus until these levels were attained or cidofovir was added. Leflunomide inhibits Polyoma virus replication in vitro and closely monitored leflunomide therapy with specifically targeted blood levels appears to be a safe and effective treatment for Polyoma BK nephropathy.Keywords
This publication has 48 references indexed in Scilit:
- Histological and immunological characteristics of, and the effect of immunosuppressive treatment on, xenograft vasculopathyXenotransplantation, 2004
- Prospective Study of Polyomavirus Type BK Replication and Nephropathy in Renal-Transplant RecipientsNew England Journal of Medicine, 2002
- Quantitation of BK Virus Load in Serum for the Diagnosis of BK Virus–Associated Nephropathy in Renal Transplant RecipientsThe Journal of Infectious Diseases, 2001
- Testing for Polyomavirus Type BK DNA in Plasma to Identify Renal-Allograft Recipients with Viral NephropathyNew England Journal of Medicine, 2000
- PHARMACOLOGICALLY INDUCED REGRESSION OF CHRONIC TRANSPLANT REJECTIONTransplantation, 1995
- IMMUNOSUPPRESSIVE EFFECTS OF LEFLUNOMIDE IN EXPERIMENTAL CHRONIC VASCULAR REJECTIONTransplantation, 1995
- Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory CompoundJournal of Biological Chemistry, 1995
- LEFLUNOMIDE IN EXPERIMENTAL TRANSPLANTATIONTransplantation, 1994
- Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomideFEBS Letters, 1993
- A Serological Investigation of BK Virus and JC Virus Infections in Recipients of Renal AllograftsThe Journal of Infectious Diseases, 1988